MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-DL-06-0014341
Kee Pharma Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹18.89 Cr
▲ 3% YoY
Net loss · FY 2025
₹80.63 Lakh
Net margin -4.3%
EBITDA · FY 2025
₹59.52 Lakh
EBITDA margin 3.2%
Authorised capital
₹11 Cr
Registered with MCA
Paid-up capital
₹10.48 Cr
Issued & subscribed
Open charges
₹9.5 Cr
Satisfied ₹4.5 Cr
Company age
35 yrs
Est. 1991
Employees · EPFO
222
Provident fund records
About Kee Pharma Limited
Data last updated:
Kee Pharma Limited is a public limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 May 1991 and has been in existence for over 35 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24239DL1991PLC044264. Its GSTIN is 07AAACK0120C1ZH (Delhi). The company holds 13 GST registrations, of which 9 are active.
The company has an authorised share capital of ₹11 Cr and a paid-up capital of ₹10.48 Cr. It was formerly known as Kee Pharma P Limited. It is led by directors including Anil Motihar (Managing Director) and Harinder Motihar.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at A – 8 3rd Floor Naraina Industrial Area Phase – II, New Delhi, Delhi, India – 110028.
As per the financials filed for FY 2025, the company reported a revenue of ₹18.89 Cr, a growth of 3% compared to the previous year. For the same year it recorded a net loss of ₹80.63 Lakh (net margin -4.3%) and EBITDA of ₹59.52 Lakh (EBITDA margin 3.2%). Revenue has grown at a compounded annual rate (CAGR) of 3% over three years and 3% over five years.
The company has about 222 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand: Kee Pharma. As per MCA filings, the company has open charges of ₹9.5 Cr and satisfied charges of ₹4.5 Cr on record. Court records list 48 cases involving the company, including 37 filed by the company and 11 filed against it; 17 cases are pending.
Kee Pharma Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-06-0014341). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website keepharma.com.
Company details
CIN U24239DL1991PLC044264
Registration Number 044264
Incorporation Date 08 May 1991
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-DL-06-0014341
Key People
Anil Motihar Managing Director Harinder Motihar Director Mohit S Nigam Additional Director Recognitions & Rankings of Kee Pharma
Contact details
Kee Pharma Limited's registered office is in New Delhi, Delhi. Its website is keepharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA – 8 3rd Floor Naraina Industrial Area Phase – II, New Delhi, Delhi, India – 110028
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Kee Pharma Limited, buy the company report.
Comprehensive company report
Kee Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Kee Pharma operates one associated brand: Kee Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Sells health supplements and products via online store. | keepharma.com |
Business activity
The main business activity of Kee Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Kee Pharma Limited, buy the company report.
Financials of Kee Pharma Limited
FY 2024 filings availableKee Pharma Limited reported revenue of ₹18.89 Cr (up 3% YoY) for FY 2025.
Revenue · FY 2025
₹18.89 Cr ▲ 3%
Net loss · FY 2025
₹80.63 Lakh margin -4.3%
EBITDA · FY 2025
₹59.52 Lakh margin 3.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 3%
3 years · compounded
▼ 3%
5 years · compounded
▲ 3%
EBITDA CAGR growth
1 year
▲ 482%
3 years · compounded
▼ 21%
5 years · compounded
▼ 3%
Revenue has grown at a compounded annual rate (CAGR) of 3% over five years, including 3% growth in the latest year. EBITDA rose 482% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹59.52 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹80.63 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.2% | ||||
| Net Profit Margin | -4.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Kee Pharma Limited, buy the company report.
Board of directors of Kee Pharma Limited
Kee Pharma has 4 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anil Motihar | Managing Director | 09 Nov 1992 | 33 Years 11 Months | Current |
| Harinder Motihar Also directs: Kee Healthcare Private Limited | Director | 31 Dec 2015 | 10 Years 10 Months | Current |
| Mohit S Nigam | Additional Director | 15 Dec 2025 | 0 Years 10 Months | Current |
| Natasha Goyal Also directs: Kati Patang Lifestyle Limited, Iboard India Limited, Hindustan Thermalprojects Limited and 2 more | Director | 22 Jul 2025 | 1 Years 3 Months | Current |
Peer comparison
Kee Pharma Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vanguard Therapeutics Private Limited | ₹18.98 Cr (FY 2025) | -19.0% | Telangana, India | |||
| Vasudha Life Science Private Limited | ₹18.95 Cr (FY 2025) | 27.0% | Brahmavara, Karnataka, India | |||
| Isera Biological Limited | ₹18.94 Cr (FY 2025) | 83.0% | Pune, Maharashtra, India | |||
| Kee Pharma Limitedthis company | ₹18.89 Cr (FY 2025) | -₹80.63 Lakh | -4.3% | 3.0% | 222 | New Delhi, Delhi, India |
| Santiago Life Sciences Private Limited | ₹18.88 Cr (FY 2024) | 5.0% | Jabalpur, Madhya Pradesh, India | |||
| Indu Drugs Private Limited | ₹18.78 Cr (FY 2025) | -10.0% | Hyderabad, Telangana, India | |||
| Gulkas Pharma Pvt Ltd | ₹18.78 Cr (FY 2025) | 21.0% | Kalol, Gujarat, India |
To see the full peer comparison of Kee Pharma Limited, buy the company report.
Auditor
Kee Pharma Limited is audited by MYMR & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MYMR & Associates | FY 2023 | 020685N |
Shareholding
The shareholding of Kee Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Kee Pharma Limited, buy the company report.
Charges & borrowings
Open charges
₹9.5 Cr
Satisfied charges
₹4.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 07 Oct 2004 | 90055951 | Indian Bank | ₹2.95 Cr | Open | |
| 11 Sep 2003 | 90043900 | Ge Capital Services India | ₹4.5 Lakh | Open | |
| 18 Oct 2002 | 90043566 | Nidian Bank | ₹75 Lakh | Open | |
| 20 Oct 2000 | 90042915 | Nidian Bank | ₹1 Cr | Open | |
| 26 Dec 1999 | 90055885 | Indian Bank | ₹8 Lakh | Open |
To see the full charge records of Kee Pharma Limited, buy the company report.
Total charge records: 13 View all charges
Legal cases
Kee Pharma Limited has 48 court cases on record: 37 filed by Kee Pharma, 11 filed against it. 17 cases are pending and 31 are disposed.
Total cases
48
Filed by the company
37
Filed against the company
11
Pending
17
Disposed
31
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 28 | 5 | 10 |
| High courts | 18 | 5 | 6 |
| Supreme Court | 2 | 1 | 1 |
Cases on record (5 of 48)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court | Appeal | Filed against the company by Official Liquidator of M/S Kingfisher Airlines Limited (in Liquidation) | Pending |
| High Court of Delhi | Court case (CS(OS)) | Filed by the company against Blue Wings Pharma Pvt Ltd & Anr | Disposed |
| High Court of Delhi | Appeal | Filed against the company by M/S Pharmex Drugs (I) Pvt Ltd Pharmex | Disposed |
| High Court of Delhi | Appeal | Filed against the company by an individual | Pending |
| District court, Gurugram, Haryana | Cheque dishonour complaint | Filed by the company against M/S Shivaay Pharmaceuticals | Pending |
To see the full case history of Kee Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Kee Pharma Limited has 14 MSME Form 1 returns on record between 2019 and 2023, listing 1,154 overdue payments to 9 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 9)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Amsar Goa Private Limited | |||
| Cure Nutraceutical Private Limited | |||
| Lenus Lifecare Pvt. Ltd. | |||
| Supermax Drugs & Pharmaceuticals Private Limited | |||
| Eastern Healthcare |
To see the full MSME payment records of Kee Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Kee Pharma has 3 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
3
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Kee Healthcare Private Limited | U24100DL2012PTC232081 | |
| Kee Diagnostics Private Limited | U24231DL2004PTC128343 | |
| Helvetica Industries Private Limited | U24233DL1999PTC098112 |
To see the full group structure of Kee Pharma Limited, buy the company report.
Employees & EPFO
Kee Pharma Limited has a workforce of 222 employees on its EPFO records as of Mar 29, 2024, across 1 active EPFO establishment.
Employee count
222
Active EPFO establishments
1
Employee growth
24.02%
GST
Kee Pharma has 13 GST registrations: 9 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
13
Active
9
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACK0120C1ZH | Delhi | Active | 01 Jul 2017 |
| 03AAACK0120C1ZP | Punjab | Active | 01 Jul 2017 |
| 09AAACK0120C1ZD | Uttar Pradesh | Active | 01 Jul 2017 |
| 10AAACK0120C1ZU | Bihar | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Kee Pharma Limited, buy the company report.
Recent activity
Kee Pharma Limited has 11 board changes on record since 1992: 4 appointments and 7 cessations. The latest: Mohit S Nigam was appointed as Additional Director on 15 Dec 2025.
Appointed
Mohit S Nigam was appointed as Additional Director.
Ceased
Natasha Goyal ceased to be Additional Director.
Appointed
Natasha Goyal was appointed as Director.
AGM
Kee Pharma Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Kee Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Ceased
Harinder Motihar ceased to be Additional Director.
Ceased
Ajit Ramrakha Bhaskar ceased to be Director.
Appointed
Harinder Motihar was appointed as Director.
Ceased
Varun Motihar ceased to be Additional Director.
Ceased
Kapil Kohli ceased to be Director.
Charges
A charge registered on 04 Nov 2008 via Charge ID 10135284 with State Bank Of India was fully satisfied on 12 Oct 2010.
Ceased
Anil Motihar ceased to be Director.
23 earlier events are in the company report.
Frequently asked questions
Kee Pharma is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 May 1991 (35+ years old) and is registered under CIN U24239DL1991PLC044264.
Kee Pharma has 4 current directors:
- Anil Motihar - Managing Director
- Harinder Motihar - Director
- Mohit S Nigam - Additional Director
- Natasha Goyal - Director
The latest financial statements of Kee Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Kee Pharma is 07AAACK0120C1ZH, registered in Delhi. The company has 13 GST registrations in all, of which 9 are active and 4 are cancelled or inactive. Other active GSTINs include 03AAACK0120C1ZP (Punjab), 09AAACK0120C1ZD (Uttar Pradesh), 10AAACK0120C1ZU (Bihar).
The CIN (Corporate Identification Number) of Kee Pharma is U24239DL1991PLC044264. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Kee Pharma has 48 court cases on record: 37 filed by the company and 11 filed against it. 17 are pending. Most are in the district courts.
Kee Pharma was incorporated on 08 May 1991, making it 35+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Kee Pharma by revenue are Vanguard Therapeutics Private Limited, Vasudha Life Science Private Limited, Isera Biological Limited, Santiago Life Sciences Private Limited, Indu Drugs Private Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Mohit S Nigam was appointed as Additional Director on 15 Dec 2025. Natasha Goyal ceased to be Additional Director on 28 Sep 2025. Natasha Goyal was appointed as Director on 22 Jul 2025. Kee Pharma has 11 board changes on record in total.
Yes, Kee Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-DL-06-0014341).
Kee Pharma has 14 MSME Form 1 returns on record between 2019 and 2023, listing 1,154 overdue payments to 9 micro and small suppliers. The latest return was filed on 05 Feb 2024.
Kee Pharma can be reached through the website keepharma.com. Its registered office is in New Delhi, Delhi, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages